Many in the AI community believe that the next major revolution will be the era of self-improving AI where AI can improve ...

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...

Anthropic’s Cowork brings Claude Code–style AI agents to the desktop, letting Claude access and manage local files and browse ...

Unless you worked for Ford’s plastics, paint and vinyls division in the 1980s, you probably don’t know the name Jim Moylan. But you might well know the idea that made this unknown engineer who ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Ashely Claudino is an Evergreen Staff Writer from Portugal. She has a Translation degree from the University of Lisbon (2020, Faculty of Arts and Humanities). Nowadays, she mostly writes Fortnite and ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...